Jay McLaughlin, Ph.D., a professor of pharmacodynamics, has been awarded an NIH-NIDA grant to study the development of CP-analogs as novel treatments for opioid use disorder.
As the incidence of opioid use disorder is growing, there remains a significant need for effective treatments to promote remission and recovery. McLaughlin is collaborating with Sparian Biosciences to develop small, oral medications for the treatment of opioid use disorder, or OUD, that improve on the current standard of care with regard to 1) improved clinical benefit 2) better safety, tolerability and lack of abusability and 3) enhanced access with improved utilization by both patients and physicians.